Kidney Res Clin Pract > Volume 41(1); 2022 > Article |
|
IgAN | Age (yr)/sex | Vaccine | Dose | Latent period (day) | Systemic sign/symptom | Initial sign | Duration of gross hematuria | Residual sign | Reporta |
---|---|---|---|---|---|---|---|---|---|
Known | 22/male | MO | 1st | 2 | Arthralgia | H, P | ND | No | Perrin et al., 2021 |
2nd | 2 | ||||||||
Known | 41/female | PB | 1st | 2 | Leukocytosis | C | ND | No | Perrin et al., 2021 |
Known | 13/male | PB | 2nd | <1 | Vomiting | H, C | 2 days | No | Hanna et al., 2021 |
Known | 38/female | MO | 2nd | 1 | Fever | H, P | 3 days | P | Negrea et al., 2021 |
Known | 38/female | MO | 2nd | 1 | Fever | H | 3 days | No | Negrea et al., 2021 |
Known | 52/female | PB | 2nd | 1 | Fever | H, P | 5 days | P | Rahim et al., 2021 |
Known | ND/male | PB | 2nd | 1 | Fever | H, P | 3 days | No | Plasse et al., 2021 |
Known | 22/female | MO | 2nd | <2 | ND | H, P | <1 month | P | Park et al., 2021 |
Known | 39/female | MO | 2nd | <2 | ND | H, P | <1 month | No | Park et al., 2021 |
Known | 27/female | PB | 2nd | 2 | Pancytopenia | H | ND | No | Perrin et al., 2021 |
Known | ND/male | PB | 2nd | 6 | Myalgia | H, C, P | ND | C, P | Plasse et al., 2021 |
Known | 78/female | MO | ND | 7 | Diarrhea | H | 15 days | No | Obeid et al., 2021 |
Known | 27/female | PB | 2nd | 2 | Fever | H, P | 4 days | No | Presenting case |
De novo | 39/male | MO | 2nd | Immediately | Fever | H, C, P | weeks | H | Anderegg et al., 2021 |
De novo | 17/male | PB | 2nd | <1 | Hypertension | H, C, P | 5 days | C, P | Hanna et al., 2021 |
De novo | 41/female | PB | 2nd | 1 | Myalgia | H, C, P | ND | ND | Tan et al., 2021 |
De novo | 50/male | MO | 2nd | 1 | Rash | H, C, P | <1 month | C, P | Park et al., 2021 |
De novo | 50/female | MO | 2nd | 2 | Fever | H, C, P | 5 days | ND | Kudose et al., 2021 |
De novo | 19/male | MO | 2nd | 2 | ND | H, C | 2 days | ND | Kudose et al., 2021 |
De novo | 30/male | MO | 2nd | 1 | Fever | H, P | 2 days | P | Abramson et al., 2021 |
C, increased creatinine; COVID-19, coronavirus disease-19; F, female; H, gross hematuria; IgAN, immunoglobulin A nephropathy; M, male; MO, Moderna; ND, no data; P, increased proteinuria; PB, Pfizer-BioNTech.
a See the Supplementary material (available online) for the references below.
Jae Seok Park
https://orcid.org/0000-0002-9927-2086
Eun Young Lee
https://orcid.org/0000-0002-4513-9888
Does Th1/Th2 cell imbalance affect immunoglobulin A nephropathy?2021 March;40(1)
Clinical Risk Factors for Bacteremia in Patients with Acute Pyelonephritis2009 September;28(5)
Acute Renal Failure Complicated by Valaciclovir in a Patient with IgA Nephropathy2008 March;27(2)